Inhibitors of egfr and methods of use thereof

Abstract

The disclosure relates to a compound having Formula (I′): and in particular, Compound I-126: which modulates the activity of EGFR, a pharmaceutical composition comprising the compound, and a method of treating or preventing a disease in which EGFR plays a role.

1 . A compound of Formula (I′): 
       
         
           
           
               
               
           
         
       
       or pharmaceutically acceptable salts, hydrates, solvates, prodrugs, stereoisomers, or tautomers thereof, wherein:
 R 1  is (C 6 -C 10 ) aryl, or heteroaryl comprising one or two 5- to 7-membered rings and 1-4 heteroatoms selected from N, O, and S, wherein the aryl and heteroaryl are each optionally substituted with one or more R 11 ; 
 each R 11  is independently selected from (C 1 -C 4 ) alkyl, (C 1 -C 4 ) haloalkyl, (C 1 -C 4 ) alkoxy, (C 1 -C 4 ) haloalkoxy, halogen, NO 2 , OH, CN, C(O)R 13 , C(O)OR 13 , C(O)NR 13 R 14 , NR 13 R 14 , (C 3 -C 7 ) cycloalkyl, heterocyclyl comprising a 5- to 7-membered ring and 1-3 heteroatoms selected from N, O, and S, (C 6 -C 10 ) aryl, and heteroaryl comprising one or two 5- to 7-membered rings and 1-4 heteroatoms selected from N, O, and S, wherein the alkyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl are each optionally substituted with one or more R 12 ; 
 each R 12  is independently selected from (C 1 -C 4 ) alkyl, (C 1 -C 4 ) haloalkyl, (C 1 -C 4 ) alkoxy, (C 1 -C 4 ) haloalkoxy, halogen, NO 2 , OH, CN, (C 3 -C 7 ) cycloalkyl, heterocyclyl comprising a 5- to 7-membered ring and 1-3 heteroatoms selected from N, O, and S, (C 6 -C 10 ) aryl, and heteroaryl comprising one or two 5- to 7-membered rings and 1-4 heteroatoms selected from N, O, and S, wherein the aryl and heteroaryl are each optionally substituted with one or more substituents independently selected from (C 1 -C 4 ) alkyl, (C 1 -C 4 ) alkoxy, (C 1 -C 4 ) haloalkyl, (C 1 -C 4 ) haloalkoxy, halogen, NH 2 , NH(C 1 -C 4 ) alkyl, N((C 1 -C 4 ) alkyl) 2 , (C 3 -C 7 ) cycloalkyl, and heterocyclyl comprising a 5- to 7-membered ring and 1-3 heteroatoms selected from N, O, and S; 
 each R 13  is independently selected from H, (C 1 -C 4 ) alkyl, (C 3 -C 7 ) cycloalkyl, and heterocyclyl comprising a 5- to 7-membered ring and 1-3 heteroatoms selected from N, O, and S, wherein the alkyl, cycloalkyl, and heterocyclyl are each optionally substituted with one or more substituents independently selected from (C 1 -C 4 ) alkyl, halogen, OH, NH 2 , NH(C 1 -C 4 ) alkyl, N((C 1 -C 4 ) alkyl) 2 , and heterocyclyl comprising a 5- to 7-membered ring and 1-3 heteroatoms selected from N, O, and S; 
 each R 14  is independently H or (C 1 -C 3 ) alkyl; 
 R 2  is H or (C 1 -C 3 ) alkyl; 
 R 3  is H or (C 1 -C 3 ) alkyl; 
 R 4  is (C 1 -C 3 ) alkyl or 
 
       
         
           
           
               
               
           
         
         X 1  is N or CR 6 ; 
         R 6  is H, (C 1 -C 4 ) alkyl, (C 1 -C 4 ) haloalkyl, (C 1 -C 4 ) alkoxy, (C 1 -C 4 ) haloalkoxy, halogen, NO 2 , NH 2 , (CH 2 ) q OH, S(O) r R 23 , or CN; 
         each R 7  is independently selected from (C 1 -C 4 ) alkyl, (C 1 -C 4 ) haloalkyl, (C 1 -C 4 ) alkoxy, (C 1 -C 4 ) haloalkoxy, halogen, NO 2 , NH 2 , (CH 2 ) q OH, S(O) r R 23 , and CN; 
         R 5  is NR 15 R 16 ; 
         R 5′  is H or (C 1 -C 4 ) alkyl; 
         R 15  is H or (C 1 -C 3 ) alkyl; 
         R 16  is (C 6 -C 10 ) aryl, or heteroaryl comprising a 5- to 7-membered ring and 1-3 heteroatoms selected from N, O, and S, wherein the aryl and heteroaryl are each optionally substituted with one or more R 18 ; or 
         R 15  and R 16  together with the nitrogen atom to which they are attached form a 5- or 6-membered heterocyclyl optionally comprising 1 or 2 additional heteroatoms selected from N, O, and S and optionally substituted with one or more oxo groups, wherein the heterocyclyl is fused with a phenyl ring which is optionally substituted with one or more R 19 ; 
         each R 18  is independently selected from (C 1 -C 4 ) alkyl, (C 1 -C 4 ) alkoxy, (C 1 -C 4 ) haloalkyl, (C 1 -C 4 ) haloalkoxy, halogen, C(O)O(C 1 -C 4 ) alkyl, NO 2 , C(O)NH(C 1 -C 4 ) alkyl, NH 2 , NH(C 1 -C 4 ) alkyl, and N((C 1 -C 4 ) alkyl) 2 , wherein the alkyl is optionally substituted with one or more substituents independently selected from halogen, OH, NH 2 , NH(C 1 -C 4 ) alkyl, and N((C 1 -C 4 ) alkyl) 2 ; 
         each R 19  is independently selected from halogen, O(CH 2 ) 1-3 —OH, (C 3 -C 7 ) cycloalkyl, (C 4 -C 7 ) cycloalkenyl, (C 6 -C 10 ) aryl, NH—(C 6 -C 10 ) aryl, and heteroaryl comprising one or two 5- to 7-membered ring and 1-4 heteroatoms selected from N, O, and S, wherein the aryl and heteroaryl are each optionally substituted with one or more R 20 ; or 
         two R 19  together with the atoms to which they are attached form a (C 6 -C 10 ) aryl optionally substituted with one or more R 20 ; 
         each R 20  is independently selected from (C 1 -C 4 ) alkyl, (C 1 -C 4 ) alkoxy, (C 1 -C 4 ) haloalkyl, (C 1 -C 4 ) haloalkoxy, halogen, C(O)OH, C(O)O(C 1 -C 4 ) alkyl, C(O)NR 21 R 22 , O(CH 2 ) 1-3 —OH, NH 2 , OH, CN, O(CH 2 ) 0-3 —(C 6 -C 10 ) aryl, and (CH 2 ) 0-3 -heterocyclyl which comprises a 5- to 7-membered ring and 1-3 heteroatoms selected from N, O, and S, wherein the heterocyclyl is optionally substituted with one or more substituents independently selected from (C 1 -C 4 ) alkyl, (C 1 -C 4 ) alkoxy, (C 1 -C 4 ) haloalkyl, (C 1 -C 4 ) haloalkoxy, halogen, NH 2 , NH(C 1 -C 4 ) alkyl, N((C 1 -C 4 ) alkyl) 2 , S(O) 2 NH 2 , (CH 2 ) s OH, C(O)(CH 2 ) s OH, and C(O)O(C 1 -C 4 ) alkyl); 
         R 21  is H or (C 1 -C 3 ) alkyl; 
         R 22  is H or (C 1 -C 4 ) alkyl optionally substituted with one or more substituents independently selected from NH 2 , NH(C 1 -C 4 ) alkyl, N((C 1 -C 4 ) alkyl) 2 , and heterocyclyl comprising a 5- to 7-membered ring and 1-3 heteroatoms selected from N, O, and S; or 
         R 21  and R 22  together with the nitrogen atom to which they are attached form a 5- or 6-membered heterocyclyl optionally containing 1-2 additional heteroatoms selected from N, O, and S; 
         R 23  is H or NH 2 ; 
         m and n are each independently 0 or 1; 
         each r and each q are independently 0, 1, or 2; 
         each s is 1 or 2; and 
         p is 0, 1, 2, 3 or 4; 
         provided that when m is 0, n is 0, p is 0, R 15  and R 16  together with the nitrogen atom to which they are attached form an unsubstituted isoindolinone, and R 6  is H, then R 1  is not 
       
       
         
           
           
               
               
           
         
       
       and
 provided that R 4  is not 4-fluoro-2-hydroxyphenyl. 
 
     
     
         2 . The compound of  claim 1 , wherein m is 0. 
     
     
         3 . The compound of any one of the preceeding claims, wherein R 5  is 
       
         
           
           
               
               
           
         
       
       optionally substituted with one to three R 19 . 
     
     
         4 . The compound of any one of the preceeding claims, wherein one R 19  is phenyl or heteroaryl comprising one or two 5- to 7-membered ring and 1-4 heteroatoms selected from N, O, and S, wherein the phenyl and heteroaryl are each optionally substituted with one or more R 20 . 
     
     
         5 . The compound of any one of the preceeding claims, wherein R 2  is halogen, O(CH 2 ) 1-3 —OH, or optionally substituted (CH 2 ) 0-3 -heterocyclyl which comprises a 5- to 7-membered ring and 1-3 heteroatoms selected from N, O, and S. 
     
     
         6 . The compound of any one of the preceeding claims, wherein R 20  is piperazinyl or piperazinyl substituted with one or more substituents independently selected from (C 1 -C 4 ) alkyl, S(O) 2 NH 2 , (CH 2 ) s OH, and C(O)(CH 2 ) s OH. 
     
     
         7 . The compound of any one of the preceeding claims, wherein R 1  is N 
       
         
           
           
               
               
           
         
       
     
     
         8 . The compound of any one of the preceeding claims, wherein R 4  is phenyl substituted with two or more R 7 . 
     
     
         9 . The compound of any one of the preceeding claims, wherein at least one R 7  is halogen or at least one R 7  is halogen and at least one R 7  is OH. 
     
     
         10 . The compound of any one of the preceeding claims, wherein n is 0. 
     
     
         11 . The compound of any one of the preceeding claims, wherein n is 1. 
     
     
         12 . A compound of the following structure 
       
         
           
           
               
               
           
         
       
       or pharmaceutically acceptable salts, hydrates, solvates, prodrugs, stereoisomers, or tautomers thereof. 
     
     
         13 . A pharmaceutical composition comprising a compound of any one of  claims 1  to  12 , and a pharmaceutically acceptable carrier. 
     
     
         14 . A method of inhibiting a kinase, comprising administering to a subject in need thereof an effective amount of a compound of any one of  claims 1  to  12 . 
     
     
         15 . A method of inhibiting epidermal growth factor receptor (EGFR), comprising administering to a subject in need thereof an effective amount of a compound of any one of  claims 1  to  12 . 
     
     
         16 . A method of treating or preventing a disease, comprising administering to a subject in need thereof an effective amount of a compound of any one of  claims 1  to  12 . 
     
     
         17 . The method of  claim 16 , wherein the disease is cancer or a proliferation disease. 
     
     
         18 . A compound of any one of  claims 1  to  12  for use in the manufacture of a medicament for treating or preventing a disease in which EGFR plays a role. 
     
     
         19 . Use of a compound of any one of  claims 1  to  12  in the treatment or prevention of a disease in which EGFR plays a role.